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Recently, a great ‘buzz’ has surrounded dronedarone — the new benzofuran antiarrhythmic
drug developed for the treatment of atrial ﬁbrillation.
The development of dronedarone has been protracted and complex. The main reason
for the complexity is not related directly to the compound, but to the pathology of the
disease. Atrial ﬁbrillation is an independent factor for increased mortality and morbidity
[1]. Nevertheless the life expectancy of most patients suffering from atrial ﬁbrillation
remains high, and it is very difﬁcult to demonstrate an effect of a drug on ‘‘hard’’ endpoints
in atrial ﬁbrillation trials, whatever the type of the therapy, pharmacological or not. Indeed
the occurrence rate of events remains low and it is necessary to do trials with a huge
number of patients and/or a long follow-up period.
Furthermore, arrhythmias are complex and multiform. Unlike some other ﬁelds of car-
diovascular therapy, the treatment of arrhythmias cannot be managed by a single drug
[2]. Antiarrhythmic drugs may act on many targets, including various ionic currents, but
also receptors and pumps. In most cases, it is much easier to control hypertension or lipid
concentrations than it is to control arrhythmias! Finally, atrial ﬁbrillation is the arrhythmia
whose mechanisms are the most complex, involving four pulmonary veins, two atria and
two vena cava, and these mechanisms may mix abnormal foci, conduction disturbances,
rotors and ganglionic plexi! In most instances, atrial ﬁbrillation occurs in elderly patients
with multiple comorbidities such as hypertension, coronary artery disease, heart failure,
valvulopathies, cardiomyopathies, sleep apnoea syndrome or obesity. . .
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For about 20 years, the safety of antiarrhythmic drugs
sed in the maintenance of sinus rhythm in atrial ﬁbrillation
atients has been questionable [3]. Following publication of
he Cardiac Arrhythmia Suppression Trial in 1989 [4], Coplen
t al., in a meta analysis published in 1990, showed that
uinidine treatment was more effective than no antiarrhyth-
ic therapy in suppressing recurrences of atrial ﬁbrillation,
ut appeared to be associated with increased total mor-
ality [5]. In the past 20 years, this major safety problem
as been evoked for all other antiarrhythmic drugs, even if
t was already clear at the time that the safety proﬁle of
uinidine itself could be unfavourable compared with other
ntiarrhythmic drugs, mainly due to the risks of QT prolon-
ation and torsades de pointes induced by the drug. For
hese past 25 years, no other new oral antiarrhythmic drug
as been developed successfully for atrial ﬁbrillation, with
he exception of dronedarone. Atrial ﬁbrillation is a seri-
us disease that can alter the patient’s quality of life and
ncrease mortality, which is a major burden for healthcare
ystems [6]. Nevertheless, the mortality rate of atrial ﬁbril-
ation remains low, around 3% per year, and it is very difﬁcult
o demonstrate, knowing this low mortality, a gain in terms
f morbimortality.
The results of the ATHENA study demonstrated a decrease
n the combined endpoint [7], i.e. hospitalisations for a car-
iovascular reason and total mortality, with dronedarone
reatment. It is not possible to consider that this success,
ever obtained with any other drugs for the past 25 years,
an be offset by the fact that dronedarone also has lim-
tations. The main limitation of dronedarone is its safety
n patients with heart failure. Dronedarone may be safe
o use in patients with hypertension, including those with
eft ventricular hypertrophy and in patients with coronary
rtery disease, as clearly demonstrated in the different tri-
ls involved in the development of dronedarone, mainly
THENA. For heart failure, the situation is more com-
lex. The results of ANDROMEDA were not in favour of
ronedarone [8], so it should be used with caution in this
opulation. The labelling obtained from the Food and Drug
dministration and from the European Medicines Agency
xcluded patients with NYHA class IV heart failure and
atients with unstable heart failure. In order to obtain the
est results with the drug, it is necessary to prescribe it
ith caution and to avoid its use in patients with class IV
ut also with class III heart failure. Indeed a large propor-
ion of patients with class III heart failure can also be those
ith unstable heart failure.
A lot of buzz currently surrounds dronedarone, includ-
ng surprising publications using data from the DIONYSOS
tudy, which had not been published [9,10]! It is without
oubt questionable to include data from a press release in
meta-analysis [9]. The role of the reviewers and the edi-
ors of prestigious, high-impact journals is to be rigorous
n ensuring accepted articles are based on robust data and
pposite methods and protocols. The results of DIONYSOS
11] —a head-to-head comparison with amiodarone— were
ot in favour of dronedarone. The design of the trial was
riginal, mainly concerning the primary composite endpoint
ixing recurrences of atrial ﬁbrillation and premature study
rug discontinuation. Indeed, the efﬁcacy of amiodarone is
ell known, but the problem in treating patients with this
rug is the necessity, in a large proportion, to discontinueJ.-Y. Le Heuzey
he drug because of side effects, mainly extracardiac, and in
ost cases, involving thyroid events. The median treatment
uration in DIONYSOS was very short, i.e. 7 months. This
rief follow-up was chosen to enable the company devel-
ping dronedarone to include the study in the registration
ossier. It was impossible to hope that the results would
avour dronedarone, however, as a short follow-up is insufﬁ-
ient to demonstrate superiority over amiodarone, knowing
hat the discontinuation of amiodarone occurs, in most of
he cases, after its extended use; a follow-up of at least
years would have been necessary. The side effects of
miodarone are frequent and generally appear after sev-
ral years of use. It is impossible to consider, as done by
he transparency commission in France, that dronedarone
oes not represent an advance compared with amiodarone.
ndeed, if a marketing authorization for a drug similar to
miodarone had been submitted in recent years, it would
ave been rejected for sure! No beneﬁt has been observed
ith amiodarone in terms of morbimortality in atrial ﬁb-
illation patients. Recently, Andersen et al. [12] published
ata from a large, unselected, population-based cohort of
atients discharged with ﬁrst-time atrial ﬁbrillation and sub-
equently treated with ﬂecainide, propafenone, sotalol or
miodarone. The results were based on data obtained in
41,500 patients included in this nationwide Danish registry.
higher annual mortality rate was observed with amio-
arone. It is possible to hypothesize that these data are due
oth to the poor safety of amiodarone and the severity of
he underlying diseases of patients for which amiodarone
as chosen.
The reality is that dronedarone is a real novelty, after
25-year absence of new antiarrhythmic drugs for patients
ith atrial ﬁbrillation, and the limitations of dronedarone
re clearly not so important as those of amiodarone.
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